(702) 204-7256

©2020 by NutraGenom. Proudly created with Wix.com

About NUTRAGENOM

Our Story

When it was launched, NUTRAGENOM’s focus was analyzing clients’ DNA for the amelioration of nutritional deficiencies due to genetic variants. The discovery of a new biotechnology—H2B—transformed its mission. Knowing that we could capture and sustain large volumes of molecular hydrogen, we recognized that we could make an important contribution to physicians and patients, while extending the benefits of our technology to address urgent problems of food production. 

 

Today, we are working with our strategic partners to launch our first flagship product, H2-Satiety Gel, an important innovation in the field of appetite control and weight loss.

 

We are also highly focused on developing the next generation of health-related products based on the H2B biotechnology. Once these are in production, we will turn our attention to seeking partners in drug delivery, medical imaging and food production.

 

We welcome enquiries from potential collaborators in these exciting ventures. If you would like to discuss participation in NUTRAGENOM’s development, please contact us here: epittz@nutragenom.com

Eugene P. Pittz, Ph.D., President and CEO: Founder

Gene earned a B.S. in Physics from Siena College, Loudonville, N.Y. and a Ph.D. in Biophysics from SUNY, Buffalo - where he did his dissertation work at Roswell Park Memorial Research Institute. Thereafter, he won a prestigious USDS-ARS Research Associate Fellowship while post-docking at Brandeis University, Waltham, MA. His research included the physical chemistry of macromolecules in relationship to water structure.

He was appointed Assistant Professor of Toxicology at the Center of Environment Toxicology, Albany Medical College. Gene had the opportunity to research the biochemical mechanisms by which some food additives and environmental chemicals cause toxicity and cancer.

Gene diversified his career by sequentially holding Senior Research and Director of R&D positions with Unilever (Lever Brothers, USA), WARNER Lambert (Pfizer), Sandoz (Novartis), Schering Plough (Merck) and MacroChem Corp. Over the course of his 25-year career with these health care companies, he designed, directed and executed numerous R&D projects in dermatology, gastroenterology, dental care as well developing new methods for drug delivery.

While over the course of holding the above positions, Gene was appointed to adjunct professor positions at the University of Tennessee and the University of Rhode Island.Gene has authored or co-authored 17 patents and 30 publications/presentations as well as winning awards for developing innovative product concepts.

He is currently a member of the American Academy of Anti-aging Medicine.